In particular, 2 weeks after the second vaccination, all HCs (28 of 28 for both IFN-γ and IL-2) and the majority of patients with IBD under immune-modifying therapies possessed positive IFN-γ (50 of 51) and IL-2 (49 of 51) responses (Figure 3B). The gene discussed is IL2; the disease is inflammatory bowel disease.